Visilizumab has been investigated for the treatment of Ulcerative Colitis.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Visilizumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Visilizumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Visilizumab. |
| Estrone | Estrone may increase the thrombogenic activities of Visilizumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Visilizumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Visilizumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Visilizumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Visilizumab. |
| Estriol | Estriol may increase the thrombogenic activities of Visilizumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Visilizumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Visilizumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Visilizumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Visilizumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Visilizumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Visilizumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Visilizumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Visilizumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Visilizumab. |
| Equol | Equol may increase the thrombogenic activities of Visilizumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Visilizumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Visilizumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Visilizumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Visilizumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Visilizumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Visilizumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Visilizumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Visilizumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Visilizumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Visilizumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Visilizumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Visilizumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Visilizumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Visilizumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Visilizumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Visilizumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Visilizumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Visilizumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Visilizumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Visilizumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Visilizumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Visilizumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Visilizumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Visilizumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Visilizumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Visilizumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Visilizumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Visilizumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Visilizumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Visilizumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Visilizumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Visilizumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Visilizumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Visilizumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Visilizumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Visilizumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Visilizumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Visilizumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Visilizumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Visilizumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Visilizumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Visilizumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Visilizumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Visilizumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Visilizumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Visilizumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Visilizumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Visilizumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Visilizumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Visilizumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Visilizumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Visilizumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Visilizumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Visilizumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Visilizumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Visilizumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Visilizumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Visilizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Visilizumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Visilizumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Visilizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Visilizumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Visilizumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Visilizumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Visilizumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Visilizumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Visilizumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Visilizumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Visilizumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Visilizumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Visilizumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Visilizumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Visilizumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Visilizumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Visilizumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Visilizumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Visilizumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Visilizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Visilizumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Visilizumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Visilizumab. |